• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与Xp11.2易位/转录因子E3基因融合相关的肾细胞癌：1例成人病例报告及文献复习

Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: an adult case report and literature review.

作者信息

Wang Yuxiong, Wang Yuantao, Feng Mingliang, Lian Xin, Lei Yongsheng, Zhou Honglan

机构信息

The Second Department of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.

出版信息

J Int Med Res. 2020 Oct;48(10):300060520942095. doi: 10.1177/0300060520942095.

DOI:10.1177/0300060520942095
PMID:33026261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7545772/
Abstract

Renal cell carcinoma (RCC) associated with Xp11.2 translocation/transcription factor E3 () gene fusion is a rare and independent subtype of RCC included in the classification of MiT (microphthalmia-associated transcriptional factor) family translocation RCC. Herein, we report an adult case of Xp11.2 translocation RCC, and review the relevant literature to improve our understanding of the pathogenesis, epidemiology, clinical manifestations, diagnosis, differential diagnosis, treatment, and other aspects of the disease.

摘要

与Xp11.2易位/转录因子E3（TFE3）基因融合相关的肾细胞癌（RCC）是RCC中一种罕见的独立亚型，被纳入MiT（小眼相关转录因子）家族易位性RCC分类中。在此，我们报告1例成人Xp11.2易位性RCC病例，并复习相关文献以增进我们对该疾病的发病机制、流行病学、临床表现、诊断、鉴别诊断、治疗及其他方面的认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/cc5f8c7f6a03/10.1177_0300060520942095-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/02fe4f38a771/10.1177_0300060520942095-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/42ae7f2b3016/10.1177_0300060520942095-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/0874c6c7be13/10.1177_0300060520942095-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/cc5f8c7f6a03/10.1177_0300060520942095-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/02fe4f38a771/10.1177_0300060520942095-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/42ae7f2b3016/10.1177_0300060520942095-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/0874c6c7be13/10.1177_0300060520942095-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cf/7545772/cc5f8c7f6a03/10.1177_0300060520942095-fig4.jpg

相似文献

1
Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: an adult case report and literature review.与Xp11.2易位/转录因子E3基因融合相关的肾细胞癌：1例成人病例报告及文献复习
J Int Med Res. 2020 Oct;48(10):300060520942095. doi: 10.1177/0300060520942095.
2
The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.沙特成年肾癌患者中与Xp11.2易位/TFE3基因融合相关的肾细胞癌发病率：一项回顾性组织芯片分析
Pol J Pathol. 2018;69(4):376-383. doi: 10.5114/pjp.2018.81697.
3
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.TFE3融合变异分析确定了Xp11易位性癌症之间特定的临床病理关联。
Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.
4
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.TFE3 断裂分离 FISH 检测与 TFE3 或组织蛋白酶 K 免疫组化染色单独检测相比，对 Xp11.2 易位相关性肾细胞癌具有更高的敏感性：扩大形态学谱。
Am J Surg Pathol. 2013 Jun;37(6):804-15. doi: 10.1097/PAS.0b013e31827e17cb.
5
Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.Xp11.2 易位性肾细胞癌中分离式荧光原位杂交检测的应用价值。
Virchows Arch. 2011 Sep;459(3):299-306. doi: 10.1007/s00428-011-1127-5. Epub 2011 Jul 20.
6
Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.Xp11.2 易位性肾肿瘤，具有 TFE3 重排相关肾细胞癌和 Xp11 易位性肾间叶肿瘤伴黑色素细胞分化特征，携带 NONO-TFE3 融合基因。
Pathol Res Pract. 2019 Sep;215(9):152521. doi: 10.1016/j.prp.2019.152521. Epub 2019 Jun 27.
7
Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis.Xp11 易位性肾细胞癌，其形态学特征类似于低度恶性潜能的多房囊性肾肿瘤：一组 6 例病例的分子分析。
J Clin Pathol. 2021 Mar;74(3):171-176. doi: 10.1136/jclinpath-2020-206681. Epub 2020 Jul 22.
8
RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.RBM10-TFE3 肾细胞癌的特征为中心体旁倒位，断裂分离荧光原位杂交显示一致的紧密分裂信号：10 例研究及文献复习。
Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.
9
A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.Xp11 易位性肾细胞癌中 TFE3 的新伴侣：临床病理分析及 EWSR1-TFE3 融合的检测。
Virchows Arch. 2019 Mar;474(3):389-393. doi: 10.1007/s00428-018-2509-8. Epub 2018 Dec 14.
10
An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.成人终末期肾病中伴SMARCB1（INI1）失活的Xp11.2易位性肾细胞癌：一例报告
Diagn Pathol. 2016 Oct 12;11(1):98. doi: 10.1186/s13000-016-0551-x.

引用本文的文献

1
Renal cell carcinoma associated with XP11.2 translocation: A case report and literature review.伴XP11.2易位的肾细胞癌：一例报告及文献复习
Urol Case Rep. 2025 May 1;61:103057. doi: 10.1016/j.eucr.2025.103057. eCollection 2025 Jul.
2
The Relevance of the Virchow Node and Virchow Triad in Renal Cancer Diagnosis.Virchow淋巴结及Virchow三联征在肾癌诊断中的相关性
Clin Pract. 2025 Jan 14;15(1):18. doi: 10.3390/clinpract15010018.
3
TFE3-rearranged RCC with osseous metaplasia found on bone mass densitometry.骨密度测定发现伴有骨化生的TFE3重排性肾细胞癌。

本文引用的文献

1
Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.国际泌尿病理学会（ISUP）关于泌尿生殖系统癌症分子病理学咨询会议报告：III：肾癌的分子病理学。
Am J Surg Pathol. 2020 Jul;44(7):e47-e65. doi: 10.1097/PAS.0000000000001476.
2
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.34 例 MiT 家族易位性肾细胞癌的综合分析及文献复习：探索预后标志物和治疗靶点。
Pathology. 2020 Apr;52(3):297-309. doi: 10.1016/j.pathol.2019.11.006. Epub 2020 Feb 24.
3
Ann Med Surg (Lond). 2024 Aug 14;86(10):6198-6202. doi: 10.1097/MS9.0000000000002479. eCollection 2024 Oct.
4
A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma.基于 TFE3 IHC 结果和临床因素的列线图作为 TFE3 重排肾细胞癌的初步筛查方案。
Cancer Med. 2024 Mar;13(5):e6813. doi: 10.1002/cam4.6813.
5
Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: A case report and literature review.伴Xp11.2易位/转录因子E3基因融合的肾细胞癌：1例报告及文献复习
Oncol Lett. 2023 Nov 21;27(1):29. doi: 10.3892/ol.2023.14162. eCollection 2024 Jan.
6
Transcription factor E3 renal cell carcinoma presenting as secondary hypertension.表现为继发性高血压的转录因子E3肾细胞癌。
Curr Urol. 2023 Mar;17(1):58-61. doi: 10.1097/CU9.0000000000000108. Epub 2022 Aug 2.
7
Xp11.2 Translocation Renal Cell Carcinoma: A Rare Renal Cell Carcinoma.Xp11.2易位性肾细胞癌：一种罕见的肾细胞癌。
Cureus. 2023 Apr 3;15(4):e37072. doi: 10.7759/cureus.37072. eCollection 2023 Apr.
8
Chemotherapy, transarterial chemoembolization, and nephrectomy combined treated one giant renal cell carcinoma (T3aN1M1) associated with Xp11.2/TFE3: A case report.化疗、经动脉化疗栓塞术及肾切除术联合治疗1例伴Xp11.2/TFE3的巨大肾细胞癌（T3aN1M1）：病例报告
World J Clin Cases. 2022 Oct 6;10(28):10180-10185. doi: 10.12998/wjcc.v10.i28.10180.
9
Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.与 Xp11.2 易位性肾细胞癌诊断后生存相关因素的系统评价和汇总分析。
Pathol Oncol Res. 2021 Mar 30;27:610360. doi: 10.3389/pore.2021.610360. eCollection 2021.
Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
携带 TFE3 基因融合的肾细胞癌中双重 mTORC1/2 抑制剂 AZD8055 的临床前疗效。
BMC Cancer. 2019 Sep 13;19(1):917. doi: 10.1186/s12885-019-6096-0.
4
MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge.MiT家族易位性肾细胞癌：从早期描述到当前认知
Cancers (Basel). 2019 Aug 3;11(8):1110. doi: 10.3390/cancers11081110.
5
RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.RBM10-TFE3 肾细胞癌的特征为中心体旁倒位，断裂分离荧光原位杂交显示一致的紧密分裂信号：10 例研究及文献复习。
Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.
6
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.具有微乳头模式的Xp11.2易位/TFE3基因融合肾细胞癌：病例报告及文献复习
Am J Transl Res. 2019 Jan 15;11(1):327-339. eCollection 2019.
7
NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.NEAT1-TFE3 和 KAT6A-TFE3 肾细胞癌，MiT 家族易位肾细胞癌的新成员。
Mod Pathol. 2019 May;32(5):710-716. doi: 10.1038/s41379-018-0191-7. Epub 2019 Jan 8.
8
Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma.程序性死亡配体-1阳性在非透明细胞肾细胞癌中的意义
J Kidney Cancer VHL. 2018 Oct 13;5(4):6-13. doi: 10.15586/jkcvhl.2018.107. eCollection 2018.
9
Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.TFE3/IRS-1/PI3K/mTOR 轴在易位性肾细胞癌中的治疗靶点。
Clin Cancer Res. 2018 Dec 1;24(23):5977-5989. doi: 10.1158/1078-0432.CCR-18-0269. Epub 2018 Jul 30.
10
Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature.机器人辅助治疗寡转移肾肿瘤合并同步胰腺转移：病例报告及文献复习
BMC Surg. 2018 Jun 13;18(1):40. doi: 10.1186/s12893-018-0371-x.